Last updated on August 2020

Study of COVID-19 DNA Vaccine (AG0301-COVID19)

Brief description of study

This study will assess the safety and immunogenicity of AG0301-COVID19 in healthy adult volunteers.

Detailed Study Description

This is a Phase 1/2, single-center, non-randomised, open-label, non-controlled trial. Approximately 30 healthy volunteers, male or female, aged 20-65, will be enrolled in the low dose group for the first 15 and the high dose group for the remaining 15.

Low dose group: 1.0 mg AG0301-COVID19 intramuscular (IM) (n = 15) High dose group: 2.0 mg AG0301-COVID19 IM (n = 15)

Clinical Study Identifier: NCT04463472

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.